Tscan therapeutics to host virtual kol event to discuss its solid tumor program strategy and highlights from the asgct 25th annual meeting

Waltham, mass., may 12, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the company will host a virtual key opinion leader (kol) event, to discuss highlights from its presentations at the american society of gene & cell therapy (asgct) 25th annual meeting as well as its solid tumor program on thursday, may 19, 2022, at 4:30 p.m. et.
TCRX Ratings Summary
TCRX Quant Ranking